Leadership

Our founders are recognized leaders in the field of genomics. Their prominent roles at comprehensive cancer centers put Agendia in an excellent position to partner with the academic world.

Mark R. Straley CHIEF EXECUTIVE OFFICER (CEO)

MARK R. STRALEY

CHIEF EXECUTIVE OFFICER (CEO)

Mr. Mark R. Straley joined Agendia Inc. in August 2015 as the company’s CEO, bringing more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services. Most recently he served as President, Anatomical Pathology of Thermo Fisher Scientific of Waltham, Massachusetts. Prior to this position he was President and CEO of Metamark Genetics of Cambridge, Massachusetts, a biotech company focusing on the development of prognostic and predictive diagnostic tests for personalized treatment of cancer patients. From 2005 to 2010, Mark held positions at Ortho Clinical Diagnostics, a J&J company, first as Worldwide Vice President of Marketing and then as Worldwide President. Prior to his assignment with J&J, Mark worked for such brand name companies as Bayer Healthcare and Abbott Laboratories where he held positions of increasing responsibility. Mark earned a Bachelor of Science degree in Marketing from Miami University.

Kurt Becker CHIEF FINANCIAL OFFICER (CFO) CHIEF OPERATING OFFICER (COO)

KURT BECKER

CHIEF FINANCIAL OFFICER (CFO)

CHIEF OPERATING OFFICER (COO)

Kurt joined Agendia in March of 2012 and has more than fifteen years of experience in financial management and analytics in healthcare, banking and aerospace industries. His previous public company experience has been at Alphatec Spine, Wells Fargo and UTC Aerospace. Kurt holds a Master’s of Science in Business Administration degree from San Diego State University with a focus on Finance and a Bachelor of Science degree in Finance from the University of Wisconsin-Milwaukee.

Chris Barbazette CHIEF COMMERCIAL OFFICER (CCO)

CHRIS BARBAZETTE

CHIEF COMMERCIAL OFFICER (CCO)

Chris Barbazette joined Agendia, Inc. in January of 2017. Chris brings more than 20 years of global experience in commercial management including direct and distributor sales, commercial marketing, product management and customer support. Before joining Agendia Chris served as Senior Vice President Global Commercial Operations for Affymetrix which was acquired by Thermo Fisher Scientific. Chris held various commercial leadership positions with increasing levels of responsibilities at Affymetrix including leading the Americas Commercial operations and establishing Affymetrix business in Latin America, Asia, Middle East, Africa and Eastern Europe. Prior to joining Affymetrix, Chris held various commercial leadership roles in leading technology companies that served the Life Science, semi-conductor, automation and paper industries. Chris has a Bachelor of Science Degree from the University of San Francisco in International Finance with a minor in Japanese language and culture.

William Audeh, MD, MS CHIEF MEDICAL OFFICER (CMO)

WILLIAM AUDEH, MD, MS

CHIEF MEDICAL OFFICER (CMO)

Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh also served as Director of the Medical Oncology Training Program for Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai, and is Associate Clinical Professor of Medicine at the UCLA David Geffen School of Medicine. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics, and targeted cancer therapy.

Dr. Audeh received his medical degree from the University of Iowa and an M.S. Degree in Genetics from the University of Minnesota. He went on to complete his residency in Internal Medicine as well as a fellowship in Medical Oncology at Stanford University Medical Center. He is board certified on internal medicine and medical oncology, and is a member of the American Society of Clinical Oncology and American Association of Cancer Research.

Prof. Laura van ‘t Veer, PhD CHIEF RESEARCH OFFICER (CRO) AND CO‑FOUNDER

PROF. LAURA VAN ‘T VEER, PhD

CHIEF RESEARCH OFFICER (CRO) AND CO‑FOUNDER

Prof. Laura van ‘t Veer, PhD, is co‑founder of Agendia and serves as its Chief Research Officer. As one of the world’s leading innovators in cancer diagnostics, she is widely recognized as a pioneer in the field of personalized medicine, also known as precision medicine. She has a 20-year track record in molecular oncology research, which includes more than 230 scientific publications and prestigious awards for her contributions to breast cancer care.

Dr. van ‘t Veer is best known for work stemming from a discovery she and her team made at the Netherlands Cancer Institute (NKI). They established that a specific DNA signature made up of 70 genes distinguished whether breast cancer tumors had a low or high risk of recurrence. After patenting their innovation, she and research partner René Bernards founded Agendia and launched the MammaPrint test.

In 2010, Dr. van ‘t Veer was appointed Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco. She is also the former head of the NKI’s DNA-diagnostic laboratory. She was awarded a 2014 European Union Prize for Women Innovators that acknowledges the ways MammaPrint has helped transform breast cancer care. In 2015, the European Patent Office (EPO) recognized MammaPrint’s impact on breast cancer diagnostics by honoring Dr. van ‘t Veer with a European Inventor Award.

Prof. Dr. René Bernards, PhD CHIEF SCIENTIFIC OFFICER (CSO) AND CO‑FOUNDER

PROF. DR. RENÉ BERNARDS, PhD

CHIEF SCIENTIFIC OFFICER (CSO) AND CO‑FOUNDER

Prof. Dr. René Bernards is Chief Scientific Officer of Agendia and also a co‑founder of the Company. René has a 30-year track record in oncology research, with more than 150 published papers in peer-reviewed journals. He is the Head of Division of Molecular Carcinogenesis of the Netherlands Cancer Institute, professor of Molecular Carcinogenesis at Utrecht University and member of the Royal Netherlands Academy of Arts and Sciences (KNAW). In addition René is a member of the Scientific Advisory Board of Gilde Healthcare fund.

Bastiaan Van Der Baan CHIEF CLINICAL AND BUSINESS DEVELOPMENT OFFICER

BASTIAAN VAN DER BAAN

CHIEF CLINICAL AND BUSINESS DEVELOPMENT OFFICER

Bas van der Baan is Chief Clinical and Business Development Officer at Agendia and joined the Company shortly after its founding in 2003. Bas holds a degree in molecular sciences and has over 15 years of healthcare experience in commercial roles, and has held positions at Unilever and other biotechnology start-ups.

Board of Directors

PATRICK J. BALTHROP, SR CHAIRMAN

PATRICK J. BALTHROP, SR

CHAIRMAN

Patrick J. Balthrop is currently a Director at Oxford Immunotec Global, Personalis, Inc. and Concert Genetics. He is an advisor to Water Street Healthcare Partners and the Founding Principal of Apalachee Ventures, an investment and advisory firm. Patrick previously held positions of CEO, President and Director at Luminex, and President at Fisher Healthcare (then Fisher Scientific). He has also held a number of positions within Abbott Laboratories, including President of Abbott Vascular and Corporate VP, Worldwide Commercial Operations. Patrick has an MBA from the Kellogg School of Management, Northwestern University and a BS in Biology from Spring Hill College.

CHRISTOPH WAER SUPERVISORY BOARD MEMBER

CHRISTOPH WAER

SUPERVISORY BOARD MEMBER, MEMBER OF THE AUDIT COMMITTEE, MEMBER OF THE TECHNICAL COMMITTEE AND MEMBER OF THE GOVERNANCE AND REMUNERATION COMMITTEE

Christoph is an investment manager at Korys, focusing on the fund investments in the life science sector in both the private and public equity market. In this capacity, he currently represents Korys on the board of MyCartis. Prior to that, he was active as a Junior Analyst in the Paris offices of Fortis Bank (now BNP Paribas) at the Corporate Finance and Capital Markets department. He then joined iPierian, a San Francisco biotech start-up company, as a financial analyst.

JAN WILLEM NIEUWENHUIZE SUPERVISORY BOARD MEMBER

JAN WILLEM NIEUWENHUIZE

SUPERVISORY BOARD MEMBER, MEMBER OF THE GOVERNANCE & REMUNERATION COMMITTEE AND MEMBER OF THE AUDIT COMMITTEE

Jan Willem Nieuwenhuize is an investment manager at ING Corporate Investments, the equity investments branch of ING Bank. Prior to joining ING in 2007, he worked for merchant bank Kempen & Co in the M&A and ECM team.

PETER STEIN SUPERVISORY BOARD MEMBER

PETER STEIN

SUPERVISORY BOARD MEMBER, MEMBER OF THE GOVERNANCE & REMUNERATION COMMITTEE

Peter Stein is the Chairman and Chief Executive Officer and principal shareholder of Norgine, an independent, specialty pharmaceutical company with operations throughout Europe. Prior to joining Norgine in 1987, Peter was a co‑founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.

ERIK LEEUWAARDEN SUPERVISORY BOARD MEMBER

ERIK LEEUWAARDEN

SUPERVISORY BOARD MEMBER, MEMBER OF THE AUDIT COMMITTEE

Erik Leeuwaarden acquired a master degree in Law and Economics. He started his career with the Dutch Ministry of Finance for twelve years. Then he became CFO of Flowerauction FloraHolland from 1992 until 2014. He now advises and supervises companies in different fields as real estate, finance, IT and trade. In 2015 Erik became a member of Agendia’s Supervisory Board.

ERIK ESVELD SUPERVISORY BOARD MEMBER

ERIK ESVELD

SUPERVISORY BOARD MEMBER

Erik Esveld acquired a Master of Science Degree in Econometrics from Erasmus University in Rotterdam. Since 2001, Erik has been the CFO at Van Herk Groep, based in Rotterdam, The Netherlands.

Where to next?

*IVDMIA = in vitro diagnostic multivariate index assay

Next-generation sequencing is a newer form of DNA sequencing technology. In addition to reducing the costs and time to sequence DNA, sequencing can be conducted with smaller samples.